The Central Vasopressinergic System: Examining the Opportunities for Psychiatric Drug Development
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Arginine vasopressin (AVP) is a cyclic nonapeptide synthesized exclusively by neurosecretory cells of the central nervous system (CNS). Two functionally distinct vasopressinergic systems can be defined based on differences in the sites of action and release of AVP. The peripheral vasopressinergic system encompasses the sites of action for AVP released into peripheral circulation (e.g. vascular smooth muscle, liver, kidney) from nerve terminals in the posterior pituitary. Peripherally circulating AVP is responsible for the classic endocrine functions ascribed to this neurohormone (e.g. vasoconstriction, glycogen metabolism, antidiuresis). The central vasopressinergic system, on the other hand, includes the sites of AVP synthesis and release within the CNS, where AVP acts as a neuromodulator/neurotransmitter regulating an array of CNS-mediated functions (e.g. learning and memory, neuroendocrine reactivity, social behaviors, circadian rhythmicity, thermoregulation, and autonomic function). Historically, pharmaceutical interest has focused on drug development efforts that sought to exploit the peripheral effects of AVP. Evidence, however, from clinical studies and animal models of CNS disorders has directly implicated disturbances in vasopressinergic activity in the pathophysiology of a number of human psychiatric disorders (mood, anxiety, and cognitive disorders). This review will examine the available evidence of central vasopressinergic system involvement in psychiatric disorders, and the potential opportunities for development of novel psychopharmaceuticals around this system will be discussed. Specific lines of evidence will be presented which rationalize each AVP receptor subtype (V(1)R or V(1a), V(2)R, V(3)R or V(1b)) as a molecular target for particular psychiatric indications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The oxytocin receptor system: structure, function, and regulation
Gimpl, G., & Fahrenholz, F. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.629 · Cited by 3,089
Sawchenko, P. E., & Swanson, L. W. (1982) · Journal of Comparative Neurology · doi:10.1002/cne.902050306 · Cited by 1,150
Corticotropin releasing activity of the new CRF is potentiated several times by vasopressin
Gillies, G. E., Linton, E. A., & Lowry, P. J. (1982) · Nature · doi:10.1038/299355a0 · Cited by 965 · cited 1×
“Acting through vasopressinergic receptors expressed on adenohypophyseal corticotrophs, primarily of the V3R (V 1b) subtype, AVP acts synergistically with corticotropin releasing factor (CRF) to stimulate adrenocorticotropin hormone (ACTH) release from the anterior pituitary into the peripheral circulation.[39] Vasopre…”
BackgroundSynthesis, transport, and release of posterior pituitary hormones
Brownstein, M. J., Russell, J. T., & Gainer, H. (1980) · Science · doi:10.1126/science.6153132 · Cited by 838 · cited 1×
“Processing of ppAVP is believed to occur during axonal transport of the peptide along the secretory pathway, which extends from the endoplasmic reticulum (ER) to the secretory granules (SC) [16].”
BackgroundRaadsheer, F. C., Hoogendijk, W. J. G., Stam, F. C., Tilders, F. J. H., & Swaab, D. F. (2008) · Neuroendocrinology · doi:10.1159/000126778 · Cited by 667
de Vries, G. J., & Buijs, R. M. (1983) · Brain Research · doi:10.1016/0006-8993(83)90855-7 · Cited by 565 · cited 2×
“The importance of the PVN to homeostatic regulation of autonomic functions suggests that these projections are responsible for vasopressinergic control of autonomic activity and nociception at the spinal level.”
BackgroundRivier, C., & Vale, W. (1983) · Nature · doi:10.1038/305325a0 · Cited by 539 · cited 1×
“Although AVP is considered to be a weak secretagogue of ACTH alone, it does act synergistically with CRF at the level of corticotrophs to potentiate ACTH release from the ‘rapidturnover’ pool [125, 126].”
BackgroundBielsky, I. F., Hu, S.-B., Szegda, K. L., Westphal, H., & Young, L. J. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300360 · Cited by 531
Cellular Mechanisms of Social Attachment
Young, L. J., Lim, M. M., Gingrich, B., & Insel, T. R. (2001) · Hormones and Behavior · doi:10.1006/hbeh.2001.1691 · Cited by 523 · cited 1×
“AVP studies in voles has featured some of the more provocative work in the field by Insel and Young, who have helped to establish the importance of central vasopressinergic function to differences in affiliative behavior and social attachment between monogamous and non-monogamous species of prairie voles [123, 124].”
BackgroundMolecular cloning and expression of a rat Via arginine vasopressin receptor
Morel, A., O'Carroll, A.-M., Brownstein, M. J., & Lolaft, S. J. (1992) · Nature · doi:10.1038/356523a0 · Cited by 477
Griebel, G., Simiand, J., Serradeil-Le Gal, C., Wagnon, J., Pascal, M., Scatton, B., Maffrand, J.-P., & Soubrié, P. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.092012099 · Cited by 471
Neuroendocrine aspects of hypercortisolism in major depression
Parker, K. J., Schatzberg, A. F., & Lyons, D. M. (2003) · Hormones and Behavior · doi:10.1016/s0018-506x(02)00016-8 · Cited by 455 · cited 1×
“Hyperactivity of the HPA axis is one of the most consistent pathological findings in patients with chronic depression, and is hallmarked by increased circulating cortisol levels [158].”
BackgroundPurba, J. S. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830020055007 · Cited by 433 · cited 1×
“Examination of post-mortem tissue from patients with depression reveals increases in the number of AVP-immunoreactive neurons in the PVN, the source of AVP released into the adenohypophyseal portal circulation [165, 166].”
BackgroundModulation of social memory in male rats by neurohypophyseal peptides
Dantzer, R., Bluthe, R. M., Koob, G. F., & Le Moal, M. (1987) · Psychopharmacology · doi:10.1007/bf00518192 · Cited by 423
Vasopressin V1b receptor knockout reduces aggressive behavior in male mice
Wersinger, S. R., Ginns, E. I., O'Carroll, A.-M., Lolait, S. J., & Young III, W. S. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001195 · Cited by 397
Morphology of vasopressin and oxytocin neurones and their central and vascular projections
Sofroniew, M. V. (1983) · Progress in Brain Research · doi:10.1016/s0079-6123(08)64378-2 · Cited by 370 · cited 1×
“In the CNS, AVP is synthesized by two types of neurons, magnocellular neurosecretory cells (MNCs) and parvocellular neurosecretory cells (PNCs) [33, 34].”
BackgroundMens, W. B. J., Witter, A., & Van Wimersma Greidanus, T. B. (1983) · Brain Research · doi:10.1016/0006-8993(83)90478-x · Cited by 360
Landgraf, R., Gerstberger, R., Montkowski, A., Probst, J., Wotjak, C., Holsboer, F., & Engelmann, M. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-06-04250.1995 · Cited by 341
Central Nervous System Effects of the Neurohypophyseal Hormones and Related Peptides
de Wied, D., Diamant, M., & Fodor, M. (1993) · Frontiers in Neuroendocrinology · doi:10.1006/frne.1993.1009 · Cited by 327
Plasma Levels of Arginine Vasopressin Elevated in Patients with Major Depression
van Londen, L. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00054-7 · Cited by 306
Pitkow, L. J., Sharer, C. A., Ren, X., Insel, T. R., Terwilliger, E. F., & Young, L. J. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-18-07392.2001 · Cited by 295 · cited 1×
“Following delivery, these animals displayed increased V1R binding that was commensurate with significant decreases in time spent in the open arms of the EPM, consistent with an anxiogenic-like effect [247].”
BackgroundCaffé, A. R., van Leeuwen, F. W., & Luiten, P. G. M. (1987) · Journal of Comparative Neurology · doi:10.1002/cne.902610206 · Cited by 286
(1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.4.656 · Cited by 278
Kim, S.-J., Young, L. J., Gonen, D., Veenstra-VanderWeele, J., Courchesne, R., Courchesne, E., Lord, C., Leventhal, B. L., Cook Jr, E. H., & Insel, T. R. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001125 · Cited by 265 · cited 19×
“To date, however, detailed descriptions of V1R immunoreactivity throughout the CNS have not been reported.”
BackgroundInfluentialSeptal vasopressin modulates social memory in male rats
Dantzer, R., Koob, G. F., Bluthe´, R.-M., & Le Moal, M. (1988) · Brain Research · doi:10.1016/0006-8993(88)90066-2 · Cited by 262
Vasopressin injected into the hypothalamus triggers a stereotypic behavior in golden hamsters
Ferris, C. F., Albers, H. E., Wesolowski, S. M., Goldman, B. D., & Luman, S. E. (1984) · Science · doi:10.1126/science.6538700 · Cited by 255 · cited 1×
“Microinjections of AVP into the CNS of hamsters produce intense stereotypic grooming and flank marking behavior in hamsters [188, 189].”
BackgroundEngelmann, M., & Landgraf, R. (1994) · Physiology & Behavior · doi:10.1016/0031-9384(94)90022-1 · Cited by 225
Ling, Y., Morgan, K., & Kalsheker, N. (2003) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(03)00133-x · Cited by 224 · cited 1×
“AD is also hallmarked by alterations in amyloid processing [209].”
BackgroundHofman, M. A., & Swaab, D. F. (1994) · Brain Research · doi:10.1016/0006-8993(94)90689-0 · Cited by 215 · cited 1×
“As AD is associated with disruptions in the oscillating diurnal and vasopressinergic activity of SCN neurons observed in younger populations, changes in SCN vasopressinergic activity may participate in disturbances of the sleep-wake cycle and endocrine rhythms that occur in this condition [197, 206-208].”
BackgroundVasopressin fiber pathways in the rat brain following suprachiasmatic nucleus lesioning
Hoorneman, E. M. D., & Buijs, R. M. (1982) · Brain Research · doi:10.1016/0006-8993(82)90246-3 · Cited by 211 · cited 1×
“Vasopressinergic efferents from the SCN target the medial preoptic area (MPA), periventricular area of the PVN (Pe), paraventricular nucleus of the thalamus (PV), and dorsomedial hypothalamic nucleus (DM) [51-54].”
BackgroundCloning and characterization of the human V3 pituitary vasopressin receptor
de Keyzer, Y., Auzan, C., Lenne, F., Beldjord, C., Thibonnier, M., Bertagna, X., & Clauser, E. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)01268-7 · Cited by 209
Vasopressin-immunoreactive cell bodies in the bed nucleus of the stria terminalis of the rat
van Leeuwen, F., & Caffé, R. (1983) · Cell and Tissue Research · doi:10.1007/bf00211473 · Cited by 206 · cited 2×
“Expression of AVP in these two structures is dependent on sex steroids, and gonadec-tomy results in a complete elimination of AVP expression among cells of BST and MeA [58].”
BackgroundFliers, E., Swaab, D. F., W. Pool, C., & Verwer, R. W. H. (1985) · Brain Research · doi:10.1016/0006-8993(85)91351-4 · Cited by 190
DeBold, C. R., Sheldon, W. R., DeCherney, G. S., Jackson, R. V., Alexander, A. N., Vale, W., Rivier, J., & Orth, D. N. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111240 · Cited by 189
Kovács, K. J., Földes, A., & Sawchenko, P. E. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-10-03843.2000 · Cited by 172 · cited 1×
“Expression of CRF and AVP in the hypothalamus is differentially responsive to circulating glucocorticoids, and evidence suggests these neuropeptides play separate roles in maintaining the responsiveness of the HPA between basal and challenged (stressful) states [132].”
BackgroundAlterations in arginine vasopressin neurons in the suprachiasmatic nucleus in depression
Zhou, J.-N., Riemersma, R. F., Unmehopa, U. A., Hoogendijk, W. J. G., van Heerikhuize, J. J., Hofman, M. A., & Swaab, D. F. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.7.655 · Cited by 172 · cited 1×
“In support of this, examination of postmortem samples from patients with major depression indicate that AVP immunoreactive cells in the SCN are abnormally increased compared to unaffected controls [176].”
ResultDe Vries, G. J., Duetz, W., Buijs, R. M., van Heerikhuize, J., & Vreeburg, J. T. M. (1986) · Brain Research · doi:10.1016/0006-8993(86)91519-2 · Cited by 153 · cited 1×
“These sites also are sex-ually dimorphic with males exhibiting more AVP immuno-reactive neurons relative to females [59].”
BackgroundThe Basic and Clinical Pharmacology of Nonpeptide Vasopressin Receptor Antagonists
Thibonnier, M., Coles, P., Thibonnier, A., & Shoham, M. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.175 · Cited by 146
Residual symptoms in depression
Fava, G. A., Fabbri, S., & Sonino, N. (2002) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(02)00226-9 · Cited by 137
Distribution of messenger RNA for the vasopressin V1a receptor in the CNS of male and female rats
Szot, P., Bale, T. L., & Dorsa, D. M. (1994) · Molecular Brain Research · doi:10.1016/0169-328x(94)90111-2 · Cited by 125 · cited 1×
“In situ hybridization studies indicate a extensive distribution of V1R throughout the CNS [74, 75].”
BackgroundBorn to be anxious: neuroendocrine and genetic correlates of trait anxiety in HAB rats
Landgraf, R., & Wigger, A. (2003) · Stress · doi:10.1080/1025389031000104193 · Cited by 122 · cited 2×
“HAB animals exhibit enhanced anxiety-like behavior in several models of anxiety-like behavior, including the elevated plus maze (EPM), social defeat paradigm, and modified hole board test [180, 181].”
Backgroundvan Kesteren, R. E., Smit, A. B., Dirks, R. W., de With, N. D., Geraerts, W. P., & Joosse, J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4593 · Cited by 120 · cited 1×
“In the oft referenced study, de Wied demonstrated that removal of the posterior and intermediate lobes of the pituitary accelerated extinction of conditioned avoidance behavior in rats without affecting its acquisition, an effect that could be normalized by peripheral administration of crude…”
BackgroundThe role of limbic vasopressin and oxytocin in social recognition
van Wimersma Greidanus, T. B., & Maigret, C. (1996) · Brain Research · doi:10.1016/0006-8993(95)01505-1 · Cited by 117
Sex Differences in Vasopressin and Other Neurotransmitter Systems in the Brain
De Vries, G. J., Buijs, R. M., & Van Leeuwen, F. W. (1984) · Progress in Brain Research · doi:10.1016/s0079-6123(08)64435-0 · Cited by 106 · cited 1×
“The projection areas for vasopressinergic neurons of the BST include the lateral habenular nucleus (LH), central grey (CG), dorsal raphe nucleus (DR), A6 cell group (locus coeruleus or LC), lateral septum (LS), vertical diagonal band of broca (MDBB), and the olfactory tubercle (Tu) [57].”
BackgroundCerebrospinal-fluid vasopressin in neurological and psychiatric-disorders
Sorensen, P. S., Gjerris, A., & Hammer, M. (1985) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.48.1.50 · Cited by 103
Persistence of attention to a novel conspecific: Some developmental variables in laboratory rats
Thor, D. H., Wainwright, K. L., & Holloway, W. R. (1982) · Developmental Psychobiology · doi:10.1002/dev.420150102 · Cited by 84 · cited 1×
“Social memory is commonly assessed by evaluating the tendency of rodents to investigate more intensely unfamiliar conspecifics than familiar ones [113].”
BackgroundDistribution and developmental changes in vasopressin V2 receptor mRNA in rat brain
Kato, Y., Igarashi, N., Hirasawa, A., Tsujimoto, G., & Kobayashi, M. (1995) · Differentiation · doi:10.1046/j.1432-0436.1995.5930163.x · Cited by 82
The vasopressin V1b receptor as a therapeutic target in stress-related disorders
Griebel, G., Simiand, J., Stemmelin, J., Gal, C., & Steinberg, R. (2003) · Current Drug Target -CNS & Neurological Disorders · doi:10.2174/1568007033482850 · Cited by 74
Inhibition of vasopressin-stimulated flank marking behavior by V1-receptor antagonists
Ferris, C. F., Singer, E. A., Meenan, D. M., & Elliott Albers, H. (1988) · European Journal of Pharmacology · doi:10.1016/0014-2999(88)90092-1 · Cited by 74 · cited 1×
“In hamsters, microinjections of V1R antagonists d(CH2)5Tyr(Me)AVP or dPenTyr(Me)AVP into the septum produced dose-dependent decreases in AVPinduced flank marking behavior [248].”
BackgroundNeuropsychological effects of vasopressin in healthy humans
Born, J., Pietrowsky, R., & L. Fehm, H. (1999) · Progress in brain research · doi:10.1016/s0079-6123(08)61595-2 · Cited by 42 · cited 4×
“for review [13]) These studies generally point to an enhancing effect for AVP on memory and cognition that is mediated, in part, by V2R receptor expression within the CNS.”
BackgroundResultInfluential
Cited by
Neumann, I. D., & Landgraf, R. (2012) · Trends in Neurosciences · doi:10.1016/j.tins.2012.08.004 · Cited by 954
Oxytocin and Vasopressin Agonists and Antagonists as Research Tools and Potential Therapeutics
Manning, M., Misicka, A., Olma, A., Bankowski, K., Stoev, S., Chini, B., Durroux, T., Mouillac, B., Corbani, M., & Guillon, G. (2012) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2012.02303.x · Cited by 423
Sex differences in oxytocin and vasopressin: Implications for autism spectrum disorders?
CARTER, C. (2007) · Behavioural Brain Research · doi:10.1016/j.bbr.2006.08.025 · Cited by 432
Gonadal steroid hormones and the hypothalamo–pituitary–adrenal axis
Handa, R. J., & Weiser, M. J. (2014) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2013.11.001 · Cited by 408
“Nonetheless, supporting roles of vasopressin and oxytocin as co-secretagogues have been also demonstrated (Herman et al., 1990; Ring, 2005).”
BackgroundNon-peptide arginine-vasopressin antagonists: the vaptans
Decaux, G., Soupart, A., & Vassart, G. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60695-9 · Cited by 376
Metadata
- Authors
- Ring, R.
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2005-01-01
- Volume
- 11
- Issue
- 2
- Pages
- 205-225
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W1974923615
- Cited by
- 139
- References
- 50
- FWCI
- 18.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.